Assessment of the skin anti-aging efficacy of a synergic treatment (food supplement and cosmetic product) based on a new full spectrum hyaluronan. A double-blind, randomized, placebo-controlled clinical study

Complife Italia Srl0 个研究点目标入组 75 人开始时间: 2020年12月30日最近更新: 2022年9月5日

试验速览

2022 Results article in https://doi.org/10.3390/cosmetics9030054 (added 24/08/2022)

•1. Good general health
•2. Females of caucasian ethnicity
•3. Photoype I to IV
•4. Age between 35 and 70 years old
•5. Mild/moderate signs of ageing (mild/moderate Crow’s feet wrinkles and mild/moderate face slackness)
•6. Subjects who have not been recently involved in any other similar study
•7. Willingness to use for face care only the creams that will be consigned at the beginning of the study
•8. Willingness to submit before and after pictures
•9. Willingness to use during all the study period only the products to be tested
•10. Willingness not to use similar products that could interfere with the product to be tested
•11. Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, etc.)
•12. Subject is under effective contraception (oral/not oral); not expected to be changed during the trial
•13. Subject aware of the study procedures and having signed an informed consent form
•14. Subjects who accept not to expose themselves in an intensive way to UV rays during the whole study duration

•1. Subjects who do not meet the inclusion criteria
•2. Pregnant/breastfeeding female or who have planned pregnancy during the study period
•3. Positive history for atopy or hypersensitive skin
•4. Subjects under systemically pharmacological treatment
•5. Subjects under locally pharmacological treatment on the skin area monitored during the test
•6. Subjects with congenital or acquired immunodeficiency
•7. Subjects under treatment with food supplements which could interfere with the functionality of the product under study
•8. Subjects which show other skin alterations on the monitored area
•9. Subjects considered as not adequate to participate in the study by the investigator
•10. Subjects with known or suspected sensitization to one or more test formulation ingredients
•11. Adult protected by law (under control or hospitalized in public or private institutions for reasons other than research, or incarcerated)
•12. Subjects not able to communicate or cooperate with the investigator for problems related to language, mental retardation or impaired brain function

发起方